UROGEN CORPORATE PRESENTATION

Cantor Virtual Global Healthcare Conference September 17, 2020



FORWARD LOOKING STATEMENTS

This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the potential market opportunity of Jelmyto in LG-UTUC; commercial plans for favorable market access and both patient and physician uptake, including the anticipated receipt of a J Code and an anticipated label update for Jelmyto; the continued successful launch of Jelmyto; the potential of UroGen's proprietary RTGel™ technology platform to improve therapeutic profiles of existing drugs to advance the treatment of specialty cancers and urologic disease; the opportunity and potential of UGN-102 for LG-NMIBC and potential advantages over TURBT; plans to commence a pivotal phase 3 trial for UGN-102 in LG NMIBC in 2020; plans to report updated durability and CR data for UGN-102 for its Phase 2B Study; the market opportunity for UGN-102 in LG-NMIBC; plans to initiate a Phase 1 study with UGN-201 in HG-NMIBC; plans to investigate UGN-201 in combination with UGN-301 (AGEN1884) in HG-NMIBC; the market opportunity and potential of UGN-301 in HG-NMIBC; plans to build a sustainable growth company; projections of revenue opportunities in markets of interest; capitalization to advance Jelmyto launch and specific clinical development programs; and plans to continue exploration of the RTGel hydrogel formulation in combination with AbbVie's portfolio of clostridial toxins in OAB and other patient populations; and financial strength and guidance. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the risks associated with Covid-19 and other pandemic risks, as more fully described in the accompanying pandemic disclosure; the timing and success of clinical trials, including the OLYMPUS Phase 3 trial, the OPTIMA II Phase 2b trial, the Atlas Phase 3 trial and potential safety and other complications thereof; the ability to obtain regulatory approval within the timeframe expected, or at all; the ability to maintain regulatory approval; complications associated with product development and commercialization activities; the labeling and packaging for any approved product; the scope, progress and expansion of developing and commercializing UroGen's product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; and UroGen's ability to attract or retain key management, members of the board of directors and personnel. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen's Form 10-Q filed with the SEC on August 10, 2020, subsequent 10-Q filings, and other filings that UroGen makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this presentation and are based on information available to UroGen as of the date of this presentation.



OUR BUSINESS COULD BE ADVERSELY AFFECTED BY THE EFFECTS OF HEALTH PANDEMICS OR EPIDEMICS, INCLUDING THE COVID-19 PANDEMIC

The recent outbreak of the novel strain of coronavirus, SARS-CoV-2, causing COVID-19 disease, which has been declared by the World Health Organization to be a pandemic, has spread across the globe and is impacting worldwide economic activity. A pandemic, including COVID-19 or other public health epidemic, poses the risk that we or our employees, contractors, suppliers, potential customers, and other partners may be prevented from conducting certain business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. While it is not possible at this time to estimate the impact that COVID-19 could have on our business, the COVID-19 pandemic and mitigation measures have had and may continue to have an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The continued spread of COVID-19 and the measures taken by various governments could disrupt the supply chain of material needed for our product candidates and our approved product, Jelmyto, interrupt healthcare services, delay coverage decisions from Medicare and third party payors, delay ongoing and planned clinical trials involving our product candidates and have a material adverse effect on our business, financial condition and results of operations. In addition, we, our customers, partners and other collaborators are or may be subject to stay-at-home orders or other mitigation measures as a result of the ongoing COVID-19 pandemic. While we, our clinical trials sites and certain of our vendors, including our third-party contract manufactures, are currently exempt from stay-at-home, shelter-in-place or similar orders for certain operations, any of the applicable exemptions may be curtailed or revoked, which would further adversely impact our business. In addition, our commercial launch of Jelmyto could be hindered by the COVID-19 pandemic, although we are currently not able to predict or quantify any such potential impact with any degree of certainty. However, the worldwide spread of the COVID-19 virus has resulted and may continue to result in a global slowdown of economic activity which is likely to decrease demand for a broad variety of goods and services, including potentially for Jelmyto, while also disrupting sales channels and marketing activities for an unknown period of time until the disease is contained. Moreover, the global outbreak of the COVID-19 coronavirus continues to rapidly evolve, and the extent to which the COVID-19 coronavirus may impact our business, results of operations and financial position will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.



LEADING IN URO-ONCOLOGY & BEYOND

Building a growth company starts with the unmet need

WE BUILD NOVEL SOLUTIONS TO TREAT SPECIALTY CANCERS AND UROLOGIC DISEASES BECAUSE PATIENTS DESERVE BETTER OPTIONS



ADDRESS CHALLENGING DISEASE WITH TRANSFORMATIVE THERAPIES

Addressing high unmet-need diseases in Urology & Gyn/Gl cancers

Must advance SOC



MAXIMIZE BENEFIT OF LOCAL DELIVERY

Leverage **RTGel capabilities and expertise** where unique solutions are needed to overcome anatomical and biological barriers

Opportunistically gain access to additional delivery platforms



PATIENT CENTRICITY

Ensure patients who can benefit from our **medicines** have **access** to them.

Provide a **holistic approach** with tools that help patients manage their disease and live their **best lives** possible



NIMBLE, SOLUTION-ORIENTED ORGANIZATION

Through our **nimble approach**, UroGen is designed to develop and commercialize medicines faster and more efficiently while creating a dynamic environment for employees

VALUES ACT BOLDLY | BE INVENTIVE | STAY CONNECTED

RTGEL[™] REVERSE-THERMAL HYDROGEL TECHNOLOGY THAT CAN POTENTIALLY SOLVE ANATOMICAL CHALLENGES IN MULTIPLE DISEASES



Exists as a liquid at lower temperatures and converts to gel form at body temperature

Has the potential to advance the treatment of specialty cancers and urologic diseases by:

- Increasing dwell time and exposure of active drugs, potentially improving the therapeutic effects of existing products
- Potentially increasing the viability of organ-sparing techniques and providing alternatives to radical surgery



UNLOCKING THE URO-ONCOLOGY MARKET-BUILDING A COMPANY

LOW-GRADE UPPER TRACT LOW-GRADE NON-MUSCULAR **UROTHELIAL CARCINOMA (UTUC) INVASIVE BLADDER CANCER (NMIBC)** Last drug ~80,000 ~6,000 - 7,000 Jelmyto – only intermediate-risk approved >15 addressable **FDA-approved** LG NMIBC population medicine years ago

~\$1 BILLION POTENTIAL PEAK REVENUE OPPORTUNITY



STRONG MOMENTUM ACROSS PIPELINE

8

PIPELINE	NONCLINICAL	PHASE 1	PHASE 2	PHASE 3	REGISTRATION	APPROVED
URO-ONCOLOGY						
Jelm yto® (m itom ycin) for py	elocalyceal solutio	on: Low-grade upp	per tract urothelia	l carcinoma (UTU)	C)	
UGN-102: Low-grade intermed	iate risk non-muscl	e invasive bladder	cancer (NMIBC)			
IMMUNO-URO-ONCOLOGY						
UGN-201 (TLR 7/8 agonist): Hi non-muscle invasive bladder c						
UGN-302: High-grade non-mu invasive bladder cancer (NMIB		UGN-201+zalif	relimab (CTLA-4)	Local Delivery		
ARTNERS	NONCLINICAL	PHASE 1	PHASE 2	PHASE 3	REGISTRATION	APPROVED
UROLOGY						
Abbvie Toxin proteins /RTGel reverse-therm al hydro	ogel					
The safety and efficacy of UGN-102, UGN-201, UGN	I-302 for the specific cope	litions have not been es	ablished			

UroGen

¹ Worldwide license agreement with Agenus; does not include Argentina, Brazil, Chile, Colombia, Peru, Venezuela and their respective territories and possessions.

JELMYTO®

Low-grade upper tract urothelial carcinoma (LG-UTUC)

JELMYTO (mitomycin) for pyelocalyceal solution; formerly known as UGN-101

FOLLOWING FDA APPROVAL, RAPID INCLUSION IN LITERATURE AND TREATMENT GUIDELINES

FDA Approval

UroGen Pharma Receives U.S. FDA Expedited Approval for Jelmyto™, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer


April 15, 2020 at 6:22 PM EDT

- Approval Based on Phase 3 Trial Results Showing a Complete Response Rate of 58%
- Median Duration of Response Has Not Been Reached
- Therapy Provides an Effective, Kidney-Sparing Option for Patients With This Rare and Difficult-To-Treat Cancer
- First-in-Class Approval Validates UroGen's Innovative Technology and Future Opportunity Across its Specialty Cancers and Urologic Diseases Portfolio
- Company to Host Conference Call on Thursday, April 16 at 8:30 AM Eastern Time

PRINCETON, N.J.--(BUSINESS WIRE)--Apr. 15, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN) today announced the U.S. Food and Drug Administration (FDA) granted expedited approval for Jelmyto[™](mitomycin) for pyelocalyceal solution, a first-in-class treatment

April 15, 2020

	-			-	•		•	
N	C		N	GL	lla	e	ine	S
	_	_						



April 28, 2020


Primary chemoablation of low-grade upper tract urothelial **⋺`⊾** () carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial ann, Surena F Matin, Phillip M Pierorazia, John I. Gore, Ahmad Shabsigh, Brian Hu, Karim Chamie, Guilherme Godoy, Scott Hubosk Marcelino Rivera, Michael O'Donnell, Marcus Quek, Jay D Raman, John J Knoedler, Douglas Scherr, Joshua Stern, Christopher Weight, Non Weizer, Michael Woods, Hristos Kaimaldiotis, Angela B Smith, Jennifer Linehan, Jonathan Coleman, Mitchell R Humphreys, Raymond Pak, David Lifshi Michael Verni Mehred Adibi Mahul RAmin Fluxe Seltzer Hitt Klein Marine Konnet v Dalit Stauss-Awali Gi Hokim Mark Scheenberg Summary Background Most patients with low-grade upper tract urothelial cancer are treated by radical nephroureterectomy. We Lange Oncol 200 atmed to assess the safety and activity of a non-surgical treatment using instillation of UGN-101, a mitromycin-April 29, 2020 containing reverse thermal gel. 1470-2045(20)30147-9 Methods In this open-label, single-arm, phase 3 trial, participants were recruited from 24 academic sites in the USA and Israel. Patients (aged >18 years) with primary or recurrent biopsy proven, low-grade upper tract urothelial cancer (measuring 5-15 mm in maximum diameter) and an Eastern Cooperative Oncology Group performance status score (measuring 2-13 mm in maximum comments), since a series of less than 3 (Karnofsky Performance Status score >40) were registered to receive six instillations of once-weekly Department of Unlog. Status UGN-101 (mitomyctn 4 mg per ml.; dosed according to volume of patient's renal pelvis and calyces, maximum 60 mg per instillation) via retrograde catheter to the renal pelvis and calyces. All patients had a planned primary disease level(NID evaluation 4-6 weeks after the completion of initial therapy, in which the primary outcome of complete response was assessed, defined as negative 3-month ureseroscopic evaluation, negative cytology, and negative for-cause biopsy. Activity (complete response, expected to occur in >15% of patients) and safety were assessed by the investigator in all Houston, TX, USA (Prof S F Matin MD, M Adihi MD) patients who received at least one dose of UGN-101. Data presented are from the data cutoff on May 22, 2019. This study is registered with ClinicalTrials.gov, NCT02793128. eween April 6, 2017, and Nov 26, 2018, 71 (96%) of 74 enrolled patients received at least one dose of UGN-101. 42 (59%, 95% CI 47-71; p<0-0001) patients had a complete response at the primary disease evaluation visit. Department of University The median follow-up for patients with a complete response was 11.0 months (IQR 5-1-12-4). The most frequently under the median for patients with a complete response was 11.0 months (IQR 5-1-12-4). The most frequently under the median formation of the median formation o haematuria in 22 (31%), flank pain in 21 (30%), and nausea in 17 (24%), 19 (27%) of 71 patients had study drug-related ent of Urology, or procedure related serious adverse events. No deaths were regarded as related to treatment tation Primary chemoablation of low-grade upper tract urothelial cancer with intracavitary UGN-101 results in (A Stability MD); Depart of Urology, Loma Linda Univenity, Loma Linda, GA, USA (B Hu MD); Department clinically significant disease eradication and might offer a kidney sparing treatment alternative for these patients. Funding UroGen Pharma. Unalogy, University of California Los Angeles, Los Angeles, CA, USA Copyright @ 2020 Elsevier Ltd. All rights reserved (KChamie MD); Departmen mantfesting as a solitary, small (<20 mm), and favourably Urology, Baylor College of Medicine, Howton, TX, USA Introduction Upper tract urothelial cancer is a rare malignancy most located lesion within the upper tract are offered kidney- (GGody MO, commonly diagnosed in patients older than 70 years preserving approaches such as endoscopic ablation.11.6 PortSPlannerMOIs and is routinely treated by radical nephroureterectorny.¹ Endoscopic surgery carries specific surgical risks and is Kennel Medical College at Bopsy grade couled with consecutional imaging data associated with a high rate of local disease recurrence? Toma Medical Consecution and urine cyclology have been integrated into European Ultimately, 70-80% of patients with low-grade and low-Association of Urology (EAU) guidelines for clinical stage upper tract urothelial cancer undergo radical stage stratification²⁺ Pattents with high-grade cancer are nephroureserectomy.³³⁹ This procedure is associated to the stage stratification and the stratification routinely offered extirpative surgery that may include with the sypical hazards of major surgery and the Bochenter, MN, USA toumby one commonly ratical neptrources recommendation of the uncert (usually additional long-term deleterious effects of renal insuffic (M Nov Mis_Department disal) or, more commonly, radical neptrources recommended and the second state of the s Conversely, 10-20% of patients with low-grade disease the potential need for dialysis dependence.73+12 www.thelancet.com/oncology_Published onlineApril 29, 2020_https://doi.org/10.1016/51470-2045/20130147-April 29, 2020


Articles

Lancet Oncology

OLYMPUS DEMONSTRATED CLINICALLY SIGNIFICANT RESPONSE WITH JELMYTO Kaplan-Meier Curve: Durability of CR as of June 2020

Complete response was achieved in over half of patients^{1,}





Most Common Adverse Events (AEs)

 Most commonly reported AEs (≥ 20%): ureteric obstruction, flank pain, urinary tract infection, hematuria, renal dysfunction, fatigue, nausea, abdominal pain, dysuria, and vomiting.


*Evaluated 4-6 weeks after up to 6 weekly instillations of JELMYTO. Complete response was determined by ureteroscopy, cytology and/or biopsy.

CI=confidence interval.

1. JELMYTO Prescribing Information. **2.** Lerner, Seth. Primary Chemoablation for the treatment of Low-Grade Upper Tract Urothelial Carcinoma: The Olympus Trial. 2020 by American Urological Association Education and Research, Inc. Important Safety Information and the full Prescribing Information available at https://www.urogen.com/download/pdf/ielmyto_prescribing.pdf



JELMYTO MARKET OPPORTUNITY: ~6-7,000 LG-UTUC ELIGIBLE PATIENTS



The First and Only Non-Surgical Treatment for Patients with LG-UTUC




LG-UTUC, A TYPE OF UROTHELIAL CARCINOMA, IS AN ORPHAN, COSTLY CANCER WITH SIGNIFICANT QOL IMPACT

LOW-GRADE UTUC

- Kidney-sparing treatments are achievable and may decrease overtreatment and loss of renal units
- 70%-80% of LG UTUC patients receive nephroureterectomies

LOW-GRADE UPPER TRACT UROTHELIAL CARCINOMA (UTUC)

Cancer that happens in the lining of the kidneys or the ureters



UC is the **most costly cancer** in the US health care system on a per-patient basis¹




ACCELERATING EARLY ADOPTION: JELMYTO®

Bringing Jelmyto to patients

MULTIPLE OPPORTUNITIES TO INCORPORATE JELMYTO INTO PHYSICIAN TREATMENT OF LG-UTUC

Treatment Continuum: Low-Grade UTUC



r = Percent of urologists who are "likely/very likely to use" UGN-101 in each specific setting.

- 70%-80% of LG UTUC patients receive nephroureterectomies
- Jelmyto may decrease the need for RNU, potentially sparing the kidney



UroGen market research, 108 urologists surveyed (March 2019), ¹Grasso et al. (2012) BJU International


SETTING A NEW STANDARD FOR LAUNCHING IN A DIGITAL WORLD



- Time on Jelmyto.com has more than doubled from June to July
 - In July **500 visitors** engaged with **3 or more pages** of content, well over industry benchmarks
- Our virtual booth had over **3,000 new users** in less than 3 months, with increased engagement rates month over month (time on site is increasing)



AWARENESS OF JELMYTO CONTINUES TO GROW SIGNIFICANTLY AS A RESULT OF COMMERCIAL EFFORTS




-Total -Hospital -Office



¹⁷ Urogen market research (Mar 18 n=106, Feb 19 n=108, Dec 19 n=108, Aug 20 n=101)

PHYSICIANS EXHIBIT MANY POSITIVE ATTITUDES FOLLOWING APPROVAL THAT WE EXPECT TO DRIVE JELMYTO UPTAKE





¹⁸ UroGen market research, 101 urologists surveyed (September 2020)

KEY COMMERCIAL ACCOMPLISHMENTS TO DATE

JELMYTO PATIENT ADOPTION

- ✓ Over 120 practices/hospitals activated as of September 1, 2020
- High volume of completed patient enrollment forms indicate future uptake in patients for Jelmyto

REIMBURSEMENT

- Claims have been paid for both commercial and Medicare with a miscellaneous code
- C code granted will have own unique code in surgery centers and hospitals
- ✓ 15 written commercial payor policies to date, providing coverage and access to ~ 82 million lives

SEAMLESS INTEGRATION INTO PHYSICIAN PRACTICE

- ✓ **5 accounts** have treated more than one patient
- ✓ National Pharmacy partner provides prepared admixture to accounts on demand
- Acceptance at major institutions, including Mayo Clinic, MD Anderson, Memorial Sloan Kettering, Johns Hopkins, Loyal University, Ohio State University, University of Indiana, University of MO



OUR PIPELINE: UGN-102

Low-grade non-muscle invasive bladder cancer (LG Intermediate Risk NMIBC)

UGN-102 (mitomycin) for intravesical solution is an investigational agent. The safety and effectiveness of UGN-102 have not been established.

WHY LG INTERMEDIATE-RISK NMIBC?

- "Surgical failure" cohort: risk of progression low, recurrence high
- Cost & morbidity of repetitive surgery

How many of the following 4 factors does the patient have?

- Multiple tumors
- Early recurrence (<1 year)
- Tumor size >3cm
- Frequent recurrences (>1 per year)



Treatment as low risk

- TURBT + single immediate post-op chemotherapeutic dose, or
- Office fulguration
- Intravesical chemotherapy

Treatment as intermediate risk

• TURBT plus adjuvant intravesical therapy

1-2


≥3

Treatment as high risk

• TURBT + BCG induction + maintenance



UROLOGISTS BECOME LESS SATISFIED WITH TURBT AMONG FREQUENTLY RECURRING PATIENTS



The subset of LG Intermediate Risk NMIBC patients fall into a cycle of frequent recurrences after repeated TURBT failures



ENCOURAGING UGN-102 PHASE 2B INTERIM TOPLINE DATA

UGN-102 enrollment completed ahead of schedule

- CR 65%* at 3-months (41/63)
- Of patients who achieved a CR and underwent an evaluation at each timepoint,
 - 97%, 86% and 85% remained disease free at six, nine and 12 months following initiation of therapy, respectively

- Kaplan-Meier analysis estimated 12-month durability at 72.4% (based on interim data)

Safety:

The majority of adverse events were reported as mild or moderate; the most commonly reported AEs (≥ 10%) were:

 dysuria, hematuria, urinary frequency, fatigue, urgency and urinary tract infection

UGN-102: POTENTIAL TO REPLACE SOC:

Moves care from **OR to office/ASC** with a potential to **decrease cost** and morbidity of contemporary therapy

*Primary endpoint of complete response based on evaluation at 3-month timepoint. Patients will continue to be followed for
durability at 12 months. Data were featured in a late-breaking abstract published in the April 2020 Supplement to The Journal of Urology



UGN-102: ~80,000 LG IR NMIBC PATIENTS

Bladder Cancer Prevalence	700,000		NIH		
Bladder Cancer Incidence	80,000		NIH		
Non Muscle Invasive BC	60,000 75% NMIB		SEER		
Low Grade NMIBC	35,000	55% of NMIBC	SEER		
Newly Diagnosed Intermediate Risk	20,000	60% Intermediate Risk	SEER AUA/SUO Joint Guideline		
Recurrent Intermediate Risk NMIBC	60,000	Recurrence rates Frequency of recurrence	Babjuk 2019 Simon 2019		
~80,000 LG IR NMIBC					

roGen


ATLAS TRIAL: UGN-102 PHASE 3 TRIAL INITIATION EXPECTED BY YEAR-END 2020 Treatment arms:

• UGN-102 +/- TURBT

TURBT

Primary endpoint: DFS

roGen




*Screening procedures to provide evidence of low grade NMIBC; no evidence of high grade disease CR = complete response, CT=computed tomography, MRI=magnetic resonance imaging, NCR= non-complete response, DFS= disease-free survival. TURBT= transurethral resection of bladder tumor. EOT=end of treatment. EOS =end of study

OUR PIPELINE: UGN-302

High-grade non-muscle invasive bladder cancer (HG-NMIBC)


UGN-302 is an investigational agent. The safety and effectiveness of UGN-302 have not been established.

UGN-302: COMBINATION INTRAVESICAL IMMUNOTHERAPY FOR BLADDER CANCER



TLR 7/8 (UGN-201): stimulate cytokines and T & B cells CTLA-4 ANTIBODY BLOCKS CTLA-4 SIGNALING CTLA-4 BT-1, BT-1, BT-2, CD28 CD2

Anti-CTLA4 UGN-301 (AG-1884): blocks "cancer masking" action of CTLA4



Ph 1&2 human data suggest UGN-201 activity in human bladder cancer

UGN-201 + UGN-301 = UGN-302: Non-clinical data suggest improved survival (murine) when 201 and a CTLA4 inhibitor are combined



STRONG BALANCE SHEET & FINANCIAL FUNDAMENTALS

STRONG FINANCIAL PROFILE

\$151.6 million in cash, cash equivalents and marketable securities, as of June 30, 2020*

Well-capitalized for Jelmyto launch and advancement of clinical development programs, including initiation of the UGN-102 Phase 3 trial in 2H 2020

22.0 million shares outstanding as of June 30, 2020

Company has no Debt on Balance Sheet



Q2 2020 10-Q Filed with the SEC on August 10, 2020
*Cash, cash equivalents, and marketable securities as of June 30, 2020 excludes restricted cash on Balance Sheet

DELIVERING TODAY, SETTING GROUNDWORK FOR TOMORROW

Launched Jelmyto, first and only non-surgical treatment for LG-UTUC, in June 2020

Achieving commercial milestones: patient identification, reimbursement and integration into physician practices

Experienced management team in place to lead the company forward

Establishing leadership in specialty cancers and urologic disease

